Syneos Health inks service deal with Pfizer

By Jenni Spinner contact

- Last updated on GMT

(AnuchaCheechang/iStock via Getty Images Plus)
(AnuchaCheechang/iStock via Getty Images Plus)

Related tags: Syneos Health, Pfizer, Clinical research, Drug development

The clinical development and consulting firm has signed a three-year service agreement to support the pharma firm with development service solutions.

Syneos Health, a contract research organization (CRO) and consulting firm, has signed a three-year service agreement with global pharmaceutical firm Pfizer. Under the terms of the agreement, Syneos Health will provide product development solutions to the drug company, with the option to extend for two additional years.

Prior to this newly signed agreement, the two companies had worked together frequently over the years. Syneos has a record of providing insights and advice regarding clinical research and commercial services to support development of various products. According to Syneos, this new agreement will continue that relationship, with the company providing service to Pfizer projects around the globe, covering a variety of therapeutic areas.

Paul Colvin, president of Syneos Health Clinical Solutions, said the pharmaceutical firm stands to benefit from his company’s range of capabilities and knowledge.

“Our ability to deliver deep therapeutic expertise, while bringing forward insights that can facilitate shorter and more efficient trials, has proven to be advantageous in our work with Pfizer​,” he said. “This new agreement allows us to continue our collaboration to deliver flexible and innovative solutions​."

We are pleased to expand our Pfizer relationship to optimize their portfolio and deliver on our shared purpose to change patients’ lives​,” Colvin added.

Earlier this year, Syneos Health senior vice president of real-world and late phase David Thompson spoke on the future of virtual/decentralized technology in clinical research and drug development​.

In March, Pfizer joined Gilead, Merck, Novartis and other pharmaceutical giants on a COVID-19 solution collaboration​, facilitated by the Bill and Melinda Gates Foundation.

Related news

Show more

Related products

show more

Flexibility and capability in pre-filled syringes

Flexibility and capability in pre-filled syringes

Curia | 15-Nov-2021 | Technical / White Paper

Pre-filled syringes have risen in popularity in recent years but the pandemic’s impact on drug development, manufacturing and patient care has created...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us


View more